Kozyk Marko, Giri Suprabhat, Harindranath Sidharth, Trivedi Manan, Strubchevska Kateryna, Barik Rakesh Kumar, Sundaram Sridhar
Department of Internal Medicine Corewell Health William Beaumont University Hospital Royal Oak Michigan USA.
Department of Gastroenterology & Hepatology Kalinga Institute of Medical Sciences Bhubaneswar India.
DEN Open. 2023 Oct 8;4(1):e294. doi: 10.1002/deo2.294. eCollection 2024 Apr.
The primary therapeutic strategy for the management of bile duct stones (BDS) is endoscopic retrograde cholangiopancreatography. However, there may be a recurrence of BDS on follow-up. Multiple risk factors have been studied for the prediction of BDS recurrence. We aimed to analyze the incidence of symptomatic BDS recurrence, systematically review the risk factors, and analyze the most important risk factors among those.
A comprehensive search of three databases was conducted from inception to November 2022 for studies reporting the recurrence of BDS recurrence after endoscopic retrograde cholangiopancreatography with clearance, along with an analysis of risk factors.
A total of 37 studies with 12,952 patients were included in the final analysis. The pooled event rate for the recurrence of BDS stones was 12.6% (95% confidence interval: 11.2-13.9). The most important risk factor was a bile duct diameter ≥15 mm, which had a significant association with recurrence in twelve studies. Other risk factors with significant association with recurrence in three or more studies were the reduced angulation of the bile duct, the presence of periampullary diverticulum, type I periampullary diverticulum, in-situ gallbladder with stones, cholecystectomy, multiple stones in the bile duct, use of mechanical lithotripsy, and bile duct stent placement.
Around one out of seven patients have BDS recurrence after the initial endoscopic retrograde cholangiopancreatography. Bile duct size and anatomy are the most important predictors of recurrence. The assessment of risk factors associated with recurrence may help keep a close follow-up in high-risk patients.
胆管结石(BDS)管理的主要治疗策略是内镜逆行胰胆管造影术。然而,随访时BDS可能会复发。已对多种风险因素进行研究以预测BDS复发。我们旨在分析有症状的BDS复发的发生率,系统回顾风险因素,并分析其中最重要的风险因素。
对三个数据库进行全面检索,从建库至2022年11月,查找报告内镜逆行胰胆管造影术结石清除术后BDS复发情况及风险因素分析的研究。
最终分析纳入了37项研究,共12952例患者。BDS结石复发的合并事件发生率为12.6%(95%置信区间:11.2 - 13.9)。最重要的风险因素是胆管直径≥15mm,在12项研究中其与复发有显著关联。在三项或更多研究中与复发有显著关联的其他风险因素包括胆管角度减小、壶腹周围憩室的存在、I型壶腹周围憩室、有结石的原位胆囊、胆囊切除术、胆管内多发结石、使用机械碎石术以及胆管支架置入。
约七分之一的患者在初次内镜逆行胰胆管造影术后会出现BDS复发。胆管大小和解剖结构是复发的最重要预测因素。对与复发相关的风险因素进行评估可能有助于对高危患者进行密切随访。